ScoreWhy is Lanzhou Foci Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 5.82%
- The company has been able to generate a Return on Capital Employed (avg) of 5.82% signifying low profitability per unit of total capital (equity and debt)
2
Flat results in Mar 26
- INTEREST(9M) At CNY 1.3 MM has Grown at 133.48%
3
With ROE of 2.69%, it has a very expensive valuation with a 2.04 Price to Book Value
- Over the past year, while the stock has generated a return of -13.87%, its profits have fallen by -21.3%
- At the current price, the company has a high dividend yield of 0.2
4
Below par performance in long term as well as near term
- Along with generating -13.87% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Lanzhou Foci Pharmaceutical Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Lanzhou Foci Pharmaceutical Co., Ltd.
-5.55%
0.15
37.03%
China Shanghai Composite
0.9%
1.20
14.07%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
5.19%
EBIT Growth (5y)
16.86%
EBIT to Interest (avg)
46.70
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.53
Tax Ratio
23.04%
Dividend Payout Ratio
20.75%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.76%
ROE (avg)
5.37%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
72
Industry P/E
Price to Book Value
1.95
EV to EBIT
72.09
EV to EBITDA
35.39
EV to Capital Employed
2.29
EV to Sales
3.40
PEG Ratio
NA
Dividend Yield
0.28%
ROCE (Latest)
3.18%
ROE (Latest)
2.69%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 326.42 MM
DIVIDEND PAYOUT RATIO(Y)
Highest at 179.64%
CASH AND EQV(HY)
Highest at CNY 1,199.86 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -29.54 %
DIVIDEND PER SHARE(HY)
Highest at CNY 1.89
-9What is not working for the Company
INTEREST(HY)
At CNY 0.55 MM has Grown at 44.91%
RAW MATERIAL COST(Y)
Grown by 13.91% (YoY
Here's what is working for Lanzhou Foci Pharmaceutical Co., Ltd.
Operating Cash Flow
Highest at CNY 326.42 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Cash and Eqv
Highest at CNY 1,199.86 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -29.54 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Dividend per share
Highest at CNY 1.89
in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (CNY)
Dividend Payout Ratio
Highest at 179.64%
in the last five yearsMOJO Watch
Company is distributing higher proportion of profits generated as dividend
DPR (%)
Here's what is not working for Lanzhou Foci Pharmaceutical Co., Ltd.
Interest
At CNY 0.55 MM has Grown at 44.91%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Raw Material Cost
Grown by 13.91% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
